Abstract
It is unclear whether standard clinical doses of risedronate affect osteocyte viability. This study examined osteocyte viability and bone remodeling rate in early postmenopausal women (1–5 years after menopause) who were treated with a standard clinical dose of risedronate (5 mg/day, orally) for 1 year. Paired transiliac bone biopsies were obtained from 19 postmenopausal women at baseline and after 1-year treatment with placebo (n = 8, mean age 52.9 ± 3.4 years) or risedronate 5 mg/day (n = 11, mean age 52.5 ± 3.4 years). In these samples, we measured osteocyte- and bone remodeling-related variables in trabecular bone. In both the placebo and risedronate groups, empty lacunae were significantly decreased after 1-year treatment compared to baseline. There were no significant differences in osteocyte-related variables between placebo and risedronate. Risedronate significantly reduced bone-remodeling indices including mineralizing surface (MS/BS), bone formation rate (BFR/BS), and activation frequency (Ac.f). Risedronate treatment caused significantly lower MS/BS and Ac.f than placebo administration. In conclusion, risedronate 5 mg/day effectively inhibited bone remodeling but did not significantly reduce osteocyte viability in trabecular bone.
Similar content being viewed by others
References
Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261
Ikeda K (2008) Osteocytes in the pathogenesis of osteoporosis. Geriatr Gerontol Int 8:213–217
O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841
Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, Kinney JH, Bonewald LF (2006) Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21:466–476
Dillaman RM, Roer RD, Gay DM (1991) Fluid movement in bone: theoretical and empirical. J Biomech 24:163–177
Burger EH, Klein-Nulend J (1999) Mechanotransduction in bone—role of the lacuno-canalicular network. FASEB J 13:S101–S112
Wang L, Ciani C, Doty SB, Fritton SP (2004) Delineating bone’s interstitial fluid pathway in vivo. Bone 34:499–509
Fosse L, Ronningen H, Benum P, Sandven RB (2006) Influence of water and fat content on compressive stiffness properties of impacted morsellized bone: an experimental ex vivo study on bone pellets. Acta Orthop 77:15–22
Frost HM (1960) Micropetrosis. J Bone Joint Surg Am 42:144–150
Qiu S, Rao DS, Palnitkar S, Parfitt AM (2002) Microdamage and missing osteocytes in human rib cortices are spatially associated and occur preferentially in interstitial bone. J Bone Miner Res 17:946
O’Brien FJ, Taylor D, Clive Lee T (2005) The effect of bone microstructure on the initiation and growth of microcracks. J Orthop Res 23:475–480
Qiu S, Rao DS, Palnitkar S, Parfitt AM (2003) Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res 18:1657–1663
Weinstein RS, Manolagas SC (2000) Apoptosis and osteoporosis. Am J Med 108:153–164
Tomkinson A, Reeve J, Shaw RW, Noble BS (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128–3135
Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS (1998) The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 13:1243–1250
Plotkin LI, Manolagas SC, Bellido T (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39:443–452
Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T (2008) Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 23:1712–1721
Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363–1374
Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB (2007) Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 40:1172–1177
Qiu S, Rao DS, Palnitkar S, Parfitt AM (2002) Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone. Bone 31:313–318
van Essen HW, Holzmann PJ, Blankenstein MA, Lips P, Bravenboer N (2007) Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. Calcif Tissue Int 81:183–190
Gidday JM (2006) Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7:437–448
Sommerschild HT, Kirkeboen KA (2002) Preconditioning—endogenous defence mechanisms of the heart. Acta Anaesthesiol Scand 46:123–137
Parfitt AM (1993) Bone age, mineral density, and fatigue damage. Calcif Tissue Int 53:S82–S86
Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620–625
Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6–16
Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62
Boyde A (2003) The real response of bone to exercise. J Anat 203:173–189
Qiu S, Sudhaker Rao D, Fyhrie DP, Palnitkar S, Parfitt AM (2005) The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 37:10–15
Fernandez-Seara MA, Wehrli SL, Takahashi M, Wehrli FW (2004) Water content measured by proton-deuteron exchange NMR predicts bone mineral density and mechanical properties. J Bone Miner Res 19:289–296
Roschger P, Paschalis EP, Fratzl P, Klaushofer K (2008) Bone mineralization density distribution in health and disease. Bone 42:456–466
Ascenzi MG, Kabo JM (2007) Method and system for modelling bone structure. Patent
Prentice AI (1967) Autofluorescence of bone tissues. J Clin Pathol 20:717–719
Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB (2003) Aging of microstructural compartments in human compact bone. J Bone Miner Res 18:1012–1019
Acknowledgement
This research was funded by The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and Sanofi-Aventis U.S.). The authors received editorial/writing support in the preparation of this article funded by The Alliance for Better Bone Health; the authors, however, were fully responsible for all content and editorial decisions and received no financial support or other form of compensation related to the development of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
S Qiu and DS Rao have received research grant support from Procter & Gamble Pharmaceuticals. DS Rao has a consultant/advisory role with NPS Pharmaceuticals and Lilly & Co. R Phipps and F Ebetino were employees of Procter & Gamble Pharmaceuticals during the period this study was performed. F Ebetino is an employee of Warner Chilcott. S Palnitkar has stated no conflict of interest.
Rights and permissions
About this article
Cite this article
Qiu, S., Phipps, R.J., Ebetino, F.H. et al. Effect of Risedronate on Osteocyte Viability and Bone Turnover in Paired Iliac Bone Biopsies from Early Postmenopausal Women. Calcif Tissue Int 87, 392–397 (2010). https://doi.org/10.1007/s00223-010-9411-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-010-9411-y